- Home
- DTST vs NCNA Comparison
DTST vs NCNA Comparison
Compare DTST & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | NCNA |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United Kingdom |
| Employees | 7 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DTST | NCNA |
|---|---|---|
| Price | $3.49 | $1.60 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 38.4K |
| Earning Date | 04-14-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $0.03 |
| 52 Week High | $5.44 | $10.00 |
Technical Indicators
Market Signals| Indicator | DTST | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 31.28 |
| Support Level | $3.06 | $1.33 |
| Resistance Level | $4.38 | $2.27 |
| Average True Range (ATR) | 0.28 | 0.15 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 38.10 | 16.23 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.